# Avalo Therapeutics, Inc.: financial statements, quarterly

AVTX · Nasdaq · CIK 1534120 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/avtx.md) · [Financials](/companies/avtx/financials.md) · [Filings](/companies/avtx/filings.md) · [Insiders](/companies/avtx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/avtx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001628280-24-045965.md) | [0.6 d](/filings/0001628280-25-013986.md) | [0.0](/filings/0001628280-24-031693.md) | [0.0](/filings/0001628280-24-036591.md) | [0.2](/filings/0001534120-25-000018.md) | [0.2 d](/filings/0001534120-26-000011.md) | not reported | not reported | [0.0](/filings/0001534120-25-000018.md) | [0.1 d](/filings/0001534120-26-000011.md) | not reported | not reported |
| Cost of revenue | $m | [0.2](/filings/0001628280-24-045965.md) | [(0.2) d](/filings/0001628280-24-013786.md) | [(0.1)](/filings/0001628280-24-031693.md) | [0.3](/filings/0001628280-25-038575.md) | [(0.7)](/filings/0001628280-24-045965.md) | not reported | not reported | [0.0](/filings/0001628280-25-038575.md) | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | [2.5](/filings/0001628280-23-038036.md) | [2.7 d](/filings/0001628280-24-013786.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.8)](/filings/0001628280-24-045965.md) | [(7.7) d](/filings/0001628280-25-013986.md) | [(32.8)](/filings/0001628280-25-024436.md) | [(9.6)](/filings/0001628280-25-038575.md) | [(12.9)](/filings/0001534120-25-000018.md) | [(13.3) d](/filings/0001534120-26-000011.md) | [(14.7)](/filings/0001534120-26-000033.md) | [(19.3)](/filings/0001534120-26-000049.md) | [(19.2)](/filings/0001534120-25-000018.md) | [(19.7) d](/filings/0001534120-26-000011.md) | [(20.9)](/filings/0001534120-26-000033.md) | [(31.5)](/filings/0001534120-26-000049.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001628280-24-045965.md) | [(0.0) d](/filings/0001628280-25-013986.md) | [0.0](/filings/0001628280-25-024436.md) | [0.0](/filings/0001628280-25-038575.md) | [(0.0)](/filings/0001534120-25-000018.md) | [0.1 d](/filings/0001534120-26-000011.md) | [0.0](/filings/0001534120-26-000033.md) | [0.0](/filings/0001534120-26-000049.md) | [0.0](/filings/0001534120-25-000018.md) | [0.1 d](/filings/0001534120-26-000011.md) | [0.0](/filings/0001534120-26-000033.md) | [0.0](/filings/0001534120-26-000049.md) |
| Net income | $m | [(5.2)](/filings/0001628280-24-045965.md) | [(8.2) d](/filings/0001628280-25-013986.md) | [(121)](/filings/0001628280-25-024436.md) | [98.5](/filings/0001628280-25-038575.md) | [23.0](/filings/0001534120-25-000018.md) | [(35.3) d](/filings/0001534120-26-000011.md) | [(13.1)](/filings/0001534120-26-000033.md) | [(20.8)](/filings/0001534120-26-000049.md) | [(30.6)](/filings/0001534120-25-000018.md) | [(13.7) d](/filings/0001534120-26-000011.md) | [(19.6)](/filings/0001534120-26-000033.md) | [(36.4)](/filings/0001534120-26-000049.md) |
| Diluted EPS | $ per share | [(26.83)](/filings/0001628280-24-045965.md) | not reported | [(141.14)](/filings/0001628280-25-024436.md) | [(14.07)](/filings/0001628280-25-038575.md) | [(2.83)](/filings/0001534120-25-000018.md) | not reported | [(1.25)](/filings/0001534120-26-000033.md) | [(1.92)](/filings/0001534120-26-000049.md) | [(2.19)](/filings/0001534120-25-000018.md) | not reported | [(0.98)](/filings/0001534120-26-000033.md) | [(0.83)](/filings/0001534120-26-000049.md) |
| Basic EPS | $ per share | [(26.83)](/filings/0001628280-24-045965.md) | not reported | [(141.14)](/filings/0001628280-25-024436.md) | [4.21](/filings/0001628280-25-038575.md) | [0.98](/filings/0001534120-25-000018.md) | not reported | [(1.25)](/filings/0001534120-26-000033.md) | [(1.92)](/filings/0001534120-26-000049.md) | [(2.19)](/filings/0001534120-25-000018.md) | not reported | [(0.98)](/filings/0001534120-26-000033.md) | [(0.83)](/filings/0001534120-26-000049.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: not reported
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [10.2](/filings/0001628280-24-045965.md) | [7.4](/filings/0001628280-25-013986.md) | [110](/filings/0001628280-25-024436.md) | [93.4](/filings/0001628280-25-038575.md) | [81.9](/filings/0001534120-25-000018.md) | [135](/filings/0001534120-26-000011.md) | [125](/filings/0001534120-26-000033.md) | [42.3](/filings/0001534120-26-000049.md) | [27.0](/filings/0001534120-25-000018.md) | [15.9](/filings/0001534120-26-000049.md) | [25.0](/filings/0001534120-26-000033.md) | [85.4](/filings/0001534120-26-000049.md) |
| Current assets | $m | [12.7](/filings/0001628280-23-038036.md) | [8.4](/filings/0001628280-25-013986.md) | [111](/filings/0001628280-24-031693.md) | [95.9](/filings/0001628280-24-036591.md) | [86.1](/filings/0001628280-24-045965.md) | [139](/filings/0001534120-26-000011.md) | [127](/filings/0001628280-25-024436.md) | [115](/filings/0001628280-25-038575.md) | [114](/filings/0001534120-25-000018.md) | [105](/filings/0001534120-26-000049.md) | [88.8](/filings/0001534120-26-000033.md) | [408](/filings/0001534120-26-000049.md) |
| Total assets | $m | [29.3](/filings/0001628280-23-038036.md) | [21.0](/filings/0001628280-25-013986.md) | [124](/filings/0001628280-24-031693.md) | [108](/filings/0001628280-24-036591.md) | [98.5](/filings/0001628280-24-045965.md) | [151](/filings/0001534120-26-000011.md) | [139](/filings/0001628280-25-024436.md) | [127](/filings/0001628280-25-038575.md) | [125](/filings/0001534120-25-000018.md) | [116](/filings/0001534120-26-000049.md) | [99.9](/filings/0001534120-26-000033.md) | [491](/filings/0001534120-26-000049.md) |
| Current liabilities | $m | [6.0](/filings/0001628280-23-038036.md) | [4.6](/filings/0001628280-25-013986.md) | [216](/filings/0001628280-24-031693.md) | [96.4](/filings/0001628280-24-036591.md) | [60.7](/filings/0001628280-24-045965.md) | [7.0](/filings/0001534120-26-000011.md) | [5.6](/filings/0001628280-25-024436.md) | [9.3](/filings/0001628280-25-038575.md) | [8.0](/filings/0001534120-25-000018.md) | [12.9](/filings/0001534120-26-000049.md) | [11.6](/filings/0001534120-26-000033.md) | [21.1](/filings/0001534120-26-000049.md) |
| Total liabilities | $m | [14.6](/filings/0001628280-23-038036.md) | [13.7](/filings/0001628280-25-013986.md) | [225](/filings/0001628280-24-031693.md) | [110](/filings/0001628280-24-036591.md) | [75.7](/filings/0001628280-24-045965.md) | [17.7](/filings/0001534120-26-000011.md) | [15.9](/filings/0001628280-25-024436.md) | [22.0](/filings/0001628280-25-038575.md) | [33.6](/filings/0001534120-25-000018.md) | [33.4](/filings/0001534120-26-000049.md) | [31.6](/filings/0001534120-26-000033.md) | [42.1](/filings/0001534120-26-000049.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [14.7](/filings/0001628280-24-045965.md) | [7.3](/filings/0001534120-26-000011.md) | [(113)](/filings/0001628280-25-038575.md) | [(13.6)](/filings/0001534120-25-000018.md) | [21.1](/filings/0001534120-25-000018.md) | [133](/filings/0001534120-26-000049.md) | [123](/filings/0001534120-26-000049.md) | [105](/filings/0001534120-26-000049.md) | [91.5](/filings/0001534120-25-000018.md) | [83.0](/filings/0001534120-26-000049.md) | [68.3](/filings/0001534120-26-000049.md) | [449](/filings/0001534120-26-000049.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(6.8) d](/filings/0001628280-24-045965.md) | [(2.8) d](/filings/0001628280-25-013986.md) | [(6.2)](/filings/0001628280-25-024436.md) | [(16.3) d](/filings/0001628280-25-038575.md) | [(11.5) d](/filings/0001534120-25-000018.md) | [(15.0) d](/filings/0001534120-26-000011.md) | [(9.5)](/filings/0001534120-26-000033.md) | [(11.4) d](/filings/0001534120-26-000049.md) | [(16.4) d](/filings/0001534120-25-000018.md) | [(14.2) d](/filings/0001534120-26-000011.md) | [(17.7)](/filings/0001534120-26-000033.md) | [(20.0) d](/filings/0001534120-26-000049.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.4](/filings/0001628280-23-038036.md) | [0.0](/filings/0001628280-24-031693.md) | [0.1](/filings/0001628280-24-036591.md) | [0.2](/filings/0001628280-24-045965.md) | [0.9](/filings/0001628280-25-024436.md) | [7.7](/filings/0001628280-25-038575.md) | [10.8](/filings/0001534120-25-000018.md) | [10.5](/filings/0001534120-26-000033.md) | [10.8](/filings/0001534120-26-000049.md) | [14.0](/filings/0001534120-25-000018.md) | [20.1](/filings/0001534120-26-000033.md) | [43.6](/filings/0001534120-26-000049.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 53,629,989 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001534120-26-000049.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.